Log in to search using one of your social media accounts:

 

Borrelia burgdorferi infection induces lipid mediator production during Lyme arthritis.

Borrelia burgdorferi infection induces lipid mediator production during Lyme arthritis. Biochimie. 2017 Jun 16;: Authors: Brown CR, Dennis EA Abstract Experimental Lyme arthritis provides a mouse model for exploring the development of pathology following infection of C3H mice with Borrelia burgdorferi. Infected mice develop a reliable inflammatory arthritis of the ankle joint with severity that typically peaks around two to three weeks post-infection and then undergoes spontaneous resolution. This makes experimental Lyme arthritis an excellent model for investigating the mechanisms that drive both the development and resolution phases of inflammatory disease. Eicosanoids are powerful lipid mediators of inflammation and are known to regulate multiple aspects of inflammatory processes. While much is known about the role of eicosanoids in regulating immune responses during autoimmune disease and cancer, relatively little is known about their role during bacterial infection. In this review, we discuss the role of eicosanoid biosynthetic pathways in mediating inflammatory responses during bacterial infection using experimental Lyme arthritis as a model system. We point out the critical role eicosanoids play in disease development and highlight surprising differences between sterile autoimmune responses and those occurring in response to bacterial infection. These differences should be kept in mind when designing therapies and treatments for inflammatory disea...
Source: Biochimie - Category: Biochemistry Authors: Tags: Biochimie Source Type: research

Related Links:

[Abstract unavailable] Language: en...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Program and Other Evaluations, Effectiveness Studies Source Type: news
[Abstract unavailable] Language: en...
Source: SafetyLit - Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news
LONDON (Reuters) - AstraZeneca's immunotherapy drug Imfinzi has won crucial approval from U.S. regulators for use in lung cancer, opening up a multibillion-dollar market for a medicine that has so far lagged behind competitors.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
This article is protected by copyright. All rights reserved.
Source: Journal of Pineal Research - Category: Research Authors: Tags: Original Article Source Type: research
AbstractThe first and family names of the authors were interchanged. The correct author names are now correctly presented in this article.
Source: European Journal of Pediatrics - Category: Pediatrics Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Review article Source Type: research
Source: Anti-Cancer Agents in Medicinal Chemistry - Category: Cancer & Oncology Authors: Tags: Research article Source Type: research
More News: Arthritis | Autoimmune Disease | Biochemistry | Borrelia | Cancer | Cancer & Oncology | Lyme Disease | Pathology | Rheumatology